Drs. Kondziolka and Lunsford have acted as consultants for Elektra Instruments.
Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery
Article first published online: 8 SEP 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 9, pages 2610–2614, 1 November 2008
How to Cite
Monaco, E., Kondziolka, D., Mongia, S., Niranjan, A., Flickinger, J. C. and Lunsford, L. D. (2008), Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery. Cancer, 113: 2610–2614. doi: 10.1002/cncr.23868
- Issue published online: 17 OCT 2008
- Article first published online: 8 SEP 2008
- Manuscript Accepted: 19 JUN 2008
- Manuscript Revised: 18 JUN 2008
- Manuscript Received: 7 FEB 2008
- ovarian carcinoma;
- endometrial carcinoma;
- brain metastases;
- stereotactic radiosurgery;
Metastases to the brain from ovarian and endometrial carcinoma are uncommon and to the authors' knowledge consensus regarding optimal management is lacking. Stereotactic radiosurgery (SRS) has proven useful for the treatment of many benign and malignant brain tumors. In the current study, the authors evaluated outcomes after SRS in patients with ovarian and endometrial carcinoma.
Twenty-seven patients with brain metastases underwent gamma–knife SRS. Six patients had endometrial carcinoma, whereas 21 patients had ovarian carcinoma. Eighteen patients also received whole–brain radiotherapy. A total of 68 tumors were treated with gamma–knife SRS.
At the time of last follow–up, 1 patient was still alive and 26 had died. The median survival was 7 months after the initial diagnosis of brain metastasis and 5 months after SRS. The 1-year survival rate after radiosurgery was 15% and that from the diagnosis of brain metastases was 22%. On final imaging, all tumors were controlled without further growth. Two patients (7.4%) developed new or progressive neurologic deficits after SRS.
SRS is an acceptable choice for the treatment of brain metastases resulting from ovarian and endometrial carcinoma, and provides local tumor control with limited morbidity. Careful patient selection is warranted in the setting of patients with uncontrolled systemic disease in whom a limited survival benefit is expected. Cancer 2008. © 2008 American Cancer Society.